Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

FibroGen, Inc. FGEN

• The company recently released topline results from its Phase 3 ZEPHYRUS-1 trial evaluating pamrevlumab's safety and efficacy in patients with idiopathic pulmonary fibrosis (IPF). The company’s stock has a 52-week low of $2.39 .
• RSI Value: 15.30
• FGEN Price Action: Shares of FibroGen gained 2.3% to close at $2.64 on Monday.

Theseus Pharmaceuticals, Inc. THRX

• Theseus Pharmaceuticals announced discontinuing enrollment in Phase 1/2 study and terminating development of THE-630 for gastrointestinal stromal tumors following two dose-limiting toxicities. It has a 52-week low of $2.62.
• RSI Value: 20.75
• THRX Price Action: Shares of Theseus Pharmaceuticals jumped 15.4% to close at $3.07 on Monday.

Silk Road Medical, Inc SILK

• JP Morgan recently downgraded the stock from Overweight to Neutral and lowered its price target from $50 to $28. The company’s stock has a 52-week low of $20.94.
• RSI Value: 25.77
• SILK Price Action: Shares of Silk Road Medical gained 3.5% to close at $22.61 on Monday.

Inogen, Inc. INGN

• Inogen agreed to purchase Physio-assist, a France-based privately-held company. The company’s 52-week low is $8.58.
• RSI Value: 29.94
• INGN Price Action: Shares of Inogen rose 2.5% to close at $9.11 on Monday.

Aadi Bioscience, Inc. AADI

• Aadi Bioscience posted better-than-expected quarterly results. "We are excited about the uptake of FYARRO and its continued sales growth after our first year on the market and believe we are operating from a position of strength with solid cash balances into 2025," said Scott Giacobello, Interim CEO and President and CFO of Aadi. The company has a 52-week low of $5.55.
• RSI Value: 26.93
• AADI Price Action: Shares of Aadi Bioscience rose 0.2% to close at $5.75 on Monday.

Read More: Fear & Greed Index Remains In 'Extreme Greed' Zone After Dow Gains For Sixth Consecutive Session